The Emulsion They Said Couldn’t Exist: Inside the Tri-Domain Architecture of NanoBase™
This is the architecture post. For the literature rebuttal -- how the papers that supposedly prove tri-domain is impossible actually prove it right -- see Tri-Domain Was Called Impossible.
Prologue: A 75-year ceiling
In 1949, William Griffin published the Hydrophilic-Lipophilic Balance. HLB is a simple, elegant number. It tells you which emulsifier keeps oil and water from separating in a jar. Seventy-five years later, it is still the default design logic running most of the cosmetic category.
HLB solved a real problem. It was never designed to solve the one the industry is actually facing now.
What HLB gives you is a stable interface -- an emulsion that does not visibly separate on the shelf. What it does not give you is engineered deposition architecture, payload-class specificity, or a colloidal population size-controlled to the sub-200 nm band. It gives you one surface, one compromise for every ingredient at once, and the assumption that arriving at the skin means the work is done.
The work is not done at the skin surface. It starts there.
Part I: Five things HLB does not account for
The gap between a stable emulsion and a delivery architecture comes down to five dimensions that HLB never modeled:
Surface charge. HLB balances hydrophilicity and lipophilicity. It says nothing about the sign or magnitude of the electrostatic charge on the droplet surface, which governs whether particles repel each other, resist coalescence, and interact productively with a charged biological barrier. A neutral droplet and a highly charged droplet can have identical HLB values.
Colloidal energy barrier. Thermodynamics drives a dispersed system toward its minimum -- a single macroscopic interface. The only question is how fast. A collision energy barrier is what slows the journey. HLB does not engineer one. It relies on viscosity and inertia, not on a designed repulsive potential.
Particle size. HLB governs emulsifier selection, not droplet diameter. Two formulas with the same HLB can produce populations at 1 um or at 185 nm, depending on processing energy, surfactant ratio, and phase geometry. Sub-200 nm behaviour -- membrane interaction, deposition characteristics, surface area per unit dose -- is a direct function of size. HLB does not touch it.
Ostwald ripening. In a polydisperse emulsion, large droplets grow and small ones shrink because of the Laplace pressure differential across curved surfaces. Over weeks and months, this erodes the sub-micron fraction that drives deposition performance. Suppressing it requires compositional engineering of the oil phase. HLB does not address it.
Multi-carrier specificity. A standard emulsion offers one environment -- one interface -- to every ingredient simultaneously. Lipophilic, hydrophilic, and amphiphilic actives all go into the same space and compete for the same surface. When a payload sits in the wrong environment, it is destabilised, undergoes degradation chemistry it would not otherwise encounter, or simply diffuses to the outer water phase and does nothing. HLB has no mechanism for assigning ingredients to dedicated domains.
These five gaps are not small. Collectively they define the difference between an emulsion and a delivery architecture.
Part II: The tri-domain answer
NanoBase™ is built from a lecithin chassis (INCI: Lecithin, Hydrogenated Phosphatidylcholine) -- a phospholipid platform the cosmetic industry has been using since Dior commercialised Capture in 1986. The chemistry is not new. The architecture is.
On a single chassis, NanoBase™ builds three coexisting colloidal environments:
A nanoemulsion domain for lipophilic payloads. Oil-soluble actives, fat-soluble vitamins, and lipid-phase ingredients sit inside the oil core of the nanodroplet population. They are protected from the aqueous continuous phase and oriented at the interface for structured delivery.
A vesicular domain for amphiphilic and structured actives. Phospholipid bilayers form spontaneously on the lecithin chassis and trap materials with both hydrophilic and lipophilic character -- peptides with fatty-acid tails, structured amphiphiles, and bilayer-compatible materials that require a membrane environment to stay functional.
A micellar domain for hydrophilic payloads. Water-soluble actives, charged peptides, and ionic materials that destabilise in the oil phase are accommodated in the aqueous-core micellar population.
The result is that every ingredient gets a domain it is chemically suited to, rather than a compromise environment optimised for none of them. This is the meaning of tri-domain: three stabilisation axes, three payload classes, one base.
Part III: What holds the three domains together
Three things, each one an engineering decision, not a lucky property of the ingredients.
The electrostatic wall. The surfaces of the nanodroplet, vesicular, and micellar populations are engineered to carry strong, stable like charge. Two identically charged objects resist each other. The colloidal populations resist coalescence for the same reason: approaching surfaces generate a repulsive potential that must be overcome before domains can merge. This is DLVO electrostatics applied as a design principle, not as a passive property. The wall does not prevent the coalescence thermodynamics wants -- it raises the energy barrier so high that coalescence effectively never happens on any timescale a finished product lives through.
Steric stabilisation. The adsorbed layer architecture at the droplet surface creates a physical, entropic resistance to droplet approach -- independent of and additive to the electrostatic barrier. When two droplet surfaces come close, the adsorbed polymer layers interpenetrate, losing conformational entropy and generating a net repulsion. This is the second barrier. Electrostatic and steric stabilisation together define a robust design window.
Ostwald ripening resistance. The oil-phase composition is engineered to suppress the Laplace-pressure-driven exchange between small and large droplets that erodes monodispersity over time. An insoluble, low-volatility oil reservoir acts as a trap: the ripening driving force is sharply reduced because diffusion through the continuous phase is thermodynamically unfavorable for a sparingly soluble oil. This holds the fine population stable across shelf life.
None of these three is a novel material. All three are documented mechanisms in the colloid-science literature. What NanoBase™ does is engineer all three simultaneously into a single lecithin-based architecture. That combination is what makes tri-domain a real, stable colloidal state rather than a mixture that separates in days.
Part IV: The thermodynamic objection, addressed
Anyone who has read colloid science will reach for the thermodynamic argument: nanoemulsions are not thermodynamically stable. Given infinite time, they phase-separate. A system with three coexisting domains is even less stable, thermodynamically speaking, than one with one.
Both points are correct. NanoBase™ does not contest either of them.
Thermodynamics sets the destination. Kinetics decides whether a system ever arrives. The three barriers above -- electrostatic, steric, Ostwald -- are kinetic stabilisers, not thermodynamic ones. They do not change where the energy minimum is. They raise the energy cost of reaching it.
Gupta, Eral, Hatton and Doyle documented this cleanly in 2016: nanoemulsions "can be kinetically stable over long time scales" despite being thermodynamically unstable (Soft Matter, DOI 10.1039/C5SM02958A). The 2024 Langmuir study on kinetically stabilised nanoemulsions names the mechanism directly: "kinetically stabilized by increasing the energy barrier for droplet coalescence" (DOI 10.1021/acs.langmuir.4c02997). The 2024 IntechOpen review on cosmetic nanoemulsions puts it plainly: "a system can be thermodynamically unstable yet kinetically stable" (DOI 10.5772/intechopen.1004740).
The 2026 comparative review in Advances in Colloid and Interface Science defines the class itself this way: nanoemulsions are "thermodynamically unstable but kinetically stable colloidal dispersions containing small fluid droplets (d < 200 nm)" (PMID 41905284).
NanoBase™ is thermodynamically unstable. It is kinetically engineered -- and that engineering is what the literature describes as sufficient.
The objection that tri-domain is thermodynamically impossible is correct and irrelevant. Thermodynamic impossibility is not the claim. Engineered kinetic stability is.
Part V: What the DLS reads -- and why PDI ~0.28 is correct
NanoBase™ is characterised every batch by multi-angle dynamic light scattering. The design target is a z-average around 185 nm.
The PDI (polydispersity index) runs at approximately 0.28. By the standard for monodisperse pharmaceutical nanoparticle preparations, that number looks wide. By the correct standard for a tri-domain cosmetic carrier, it is the expected fingerprint.
A monodisperse preparation contains one population. Its DLS returns a narrow, sharp peak -- low PDI, high symmetry. A tri-domain preparation contains three coexisting populations: nanodroplets, vesicles, and micelles, each with its own size range. When those three overlapping populations are read by DLS, the instrument returns a composite distribution. The composite is broader than any single population would be. PDI ~0.28 is not a quality problem. It is the DLS signature of genuine multi-population architecture.
The published technical specification on Zenodo (https://zenodo.org/records/18616576) documents both the target and the rationale.
Part VI: Cosmetic scope -- deposition, not force
NanoBase™ is a leave-on cosmetic system for intact skin and hair, regulated as a cosmetic under the US FD&C Act §201(i) and EU Cosmetics Regulation (EC) No 1223/2009. Its claim domain is the skin surface and stratum corneum -- deposition, not medical action.
The design rationale for sub-200 nm architecture in a leave-on format is surface-area-dependent. A 185 nm droplet presents roughly fifty times the surface area per gram as a 1 um droplet. A finer, more uniform population contacts the skin topography more evenly and distributes payloads across the stratum corneum surface more completely than a macro-emulsion does. This is a physical consequence of geometry, characterised in the cosmetic literature through standard industry methods including tape-strip deposition assays, Franz-cell diffusion modelling, and confocal Raman depth profiling -- the established toolbox for quantifying how vehicle architecture affects stratum corneum distribution.
The benefit is consistency and breadth, not force. NanoBase™ is engineered to reduce surface resistance and support even stratum corneum deposition, so the skin surface can interact with the domains it needs, across a wide range of users.
Part VII: The open evidence trail
Nothing about NanoBase™ architecture is proprietary at the mechanism level. The mechanisms are textbook: DLVO electrostatics, steric entropic repulsion, Ostwald ripening suppression, phospholipid vesicle self-assembly. The engineering is in applying all three in one architecture while holding the size target at 185 nm.
The published technical specification (https://zenodo.org/records/18616576) gives the architecture's characterisation parameters as a citable, timestamped public record.
The literature that establishes the kinetic-stability case:
Gupta, Eral, Hatton & Doyle (2016). Nanoemulsions: formation, properties and applications. Soft Matter 12, 2826. https://doi.org/10.1039/C5SM02958A
Langmuir 2024, 40(41), 21814 (Phase-Change Nanoemulsions). https://doi.org/10.1021/acs.langmuir.4c02997
Ajayi (2024). Thermodynamic and Kinetic Stability of Cosmetic Nanoemulsions. IntechOpen. https://doi.org/10.5772/intechopen.1004740
Microemulsions versus nanoemulsions: A comparative overview (2026). Advances in Colloid and Interface Science. PMID 41905284.
NanoBase™ is a cosmetic delivery architecture for leave-on application to intact skin and hair. All claims are cosmetic-scope. Performance references in this post describe the sub-200 nm particle-size class as characterised in the cosmetic-science literature; they are not asserted as in-vivo clinical results on NanoBase™ formulations. The Zenodo-deposited technical note is an open technical record, not a clinical study.
Explore the NanoBase™ architecture, or reach the lab through Lab Services and Formulation Services.
